Hangzhou Tigermed Consulting Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Hangzhou Tigermed Consulting kazanç ve gelirin sırasıyla yıllık 38.1% ve 16.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 38.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 8.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

38.1%

Kazanç büyüme oranı

38.3%

EPS büyüme oranı

Life Sciences kazanç büyümesi	34.7%
Gelir büyüme oranı	16.8%
Gelecekteki özkaynak getirisi	8.8%
Analist kapsamı	Good
Son güncelleme	01 Nov 2024

Gelecekteki son büyüme güncellemeleri

Hangzhou Tigermed Consulting Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 28

Recent updates

Hangzhou Tigermed Consulting Co., Ltd's (SZSE:300347) Share Price Could Signal Some Risk

Aug 21

Hangzhou Tigermed Consulting (SZSE:300347) Is Increasing Its Dividend To CN¥0.568

Jul 12

Is Hangzhou Tigermed Consulting (SZSE:300347) A Risky Investment?

Jun 26

An Intrinsic Calculation For Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Suggests It's 35% Undervalued

Jun 07

Hangzhou Tigermed Consulting Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 28

Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Stock Catapults 27% Though Its Price And Business Still Lag The Market

Apr 08

Hangzhou Tigermed Consulting's (SZSE:300347) Profits Appear To Have Quality Issues

Apr 04

Hangzhou Tigermed Consulting Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models

Apr 01

Kazanç ve Gelir Büyüme Tahminleri

SZSE:300347 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	9,760	2,372	1,738	2,227	18
12/31/2025	8,561	2,028	1,634	2,010	20
12/31/2024	6,859	1,272	1,055	1,112	5
9/30/2024	6,801	959	678	1,057	N/A
6/30/2024	7,031	1,129	594	953	N/A
3/31/2024	7,240	1,691	924	1,266	N/A
12/31/2023	7,384	2,025	837	1,150	N/A
9/30/2023	7,330	2,281	866	1,205	N/A
6/30/2023	7,202	2,203	964	1,373	N/A
3/31/2023	7,072	2,057	613	1,083	N/A
1/1/2023	7,085	2,007	909	1,358	N/A
9/30/2022	7,225	2,698	1,098	1,521	N/A
6/30/2022	6,751	2,811	917	1,299	N/A
3/31/2022	6,129	2,937	1,189	1,489	N/A
1/1/2022	5,214	2,874	1,055	1,424	N/A
9/30/2021	4,287	2,213	930	1,210	N/A
6/30/2021	3,797	2,006	976	1,263	N/A
3/31/2021	3,444	1,950	895	1,148	N/A
12/31/2020	3,192	1,750	842	999	N/A
9/30/2020	3,073	1,632	558	704	N/A
6/30/2020	2,918	1,488	524	621	N/A
3/31/2020	2,845	951	452	565	N/A
12/31/2019	2,803	842	425	528	N/A
9/30/2019	2,737	682	386	518	N/A
6/30/2019	2,605	606	356	450	N/A
3/31/2019	2,436	522	387	488	N/A
12/31/2018	2,301	472	431	522	N/A
9/30/2018	2,107	419	458	521	N/A
6/30/2018	1,977	400	N/A	404	N/A
3/31/2018	1,805	354	N/A	312	N/A
12/31/2017	1,687	301	N/A	315	N/A
9/30/2017	1,500	241	N/A	272	N/A
6/30/2017	1,352	182	N/A	281	N/A
3/31/2017	1,255	144	N/A	305	N/A
12/31/2016	1,175	141	N/A	192	N/A
9/30/2016	1,150	145	N/A	176	N/A
6/30/2016	1,096	159	N/A	156	N/A
3/31/2016	1,015	161	N/A	135	N/A
12/31/2015	957	156	N/A	186	N/A
9/30/2015	862	151	N/A	98	N/A
6/30/2015	821	147	N/A	100	N/A
3/31/2015	725	135	N/A	87	N/A
12/31/2014	625	125	N/A	44	N/A
9/30/2014	510	112	N/A	46	N/A
6/30/2014	401	102	N/A	59	N/A
3/31/2014	377	99	N/A	57	N/A
12/31/2013	337	94	N/A	77	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 300347 'nin tahmini kazanç büyümesi (yıllık 38.1% ) tasarruf oranının ( 2.9% ) üzerindedir.

Kazançlar ve Piyasa: 300347 şirketinin kazançlarının (yıllık 38.1% ) CN pazarından (yıllık 25.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 300347 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 300347 şirketinin gelirinin (yıllık 16.8% ) CN pazarından (yıllık 14.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 300347 şirketinin gelirinin (yıllık 16.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 300347 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 8.8 %).

Hangzhou Tigermed Consulting Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 15% to CN¥61.67

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 15%

Consensus EPS estimates fall by 19%

Hangzhou Tigermed Consulting Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Price target decreased by 9.0% to CN¥60.82

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 15% to CN¥61.67

Investor sentiment deteriorates as stock falls 23%

Now 26% undervalued

New minor risk - Share price stability

Hangzhou Tigermed Consulting Co., Ltd to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 18%

Consensus EPS estimates fall by 12%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Hangzhou Tigermed Consulting Co., Ltd's (SZSE:300347) Share Price Could Signal Some Risk

Hangzhou Tigermed Consulting (SZSE:300347) Is Increasing Its Dividend To CN¥0.568

Dividend increased to CN¥0.57

Hangzhou Tigermed Consulting Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024

Is Hangzhou Tigermed Consulting (SZSE:300347) A Risky Investment?

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

An Intrinsic Calculation For Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Suggests It's 35% Undervalued

Consensus EPS estimates increase by 15%

Consensus EPS estimates fall by 19%

Hangzhou Tigermed Consulting Co., Ltd, Annual General Meeting, May 24, 2024

Hangzhou Tigermed Consulting Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 9.0% to CN¥60.82

Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Stock Catapults 27% Though Its Price And Business Still Lag The Market

Hangzhou Tigermed Consulting's (SZSE:300347) Profits Appear To Have Quality Issues

Consensus revenue estimates fall by 11%

Hangzhou Tigermed Consulting Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models

Hangzhou Tigermed Consulting Co., Ltd to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Hangzhou Tigermed Consulting Co., Ltd Announces Final Dividend for the Year Ended December 31, 2023, Payable on 31 July 2024

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

Investor sentiment improves as stock rises 27%

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 7.9% to CN¥72.81

Hangzhou Tigermed Consulting Co., Ltd to Report Fiscal Year 2023 Results on Mar 29, 2024

Price target decreased by 17% to CN¥79.10

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 7.5% to CN¥116

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

Hangzhou Tigermed Consulting Co., Ltd. Announces Final Profit Distribution Plan Implementation (A Shares) for 2022, Payable on 07 July 2023

Hangzhou Tigermed Consulting Co. Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2022, Payable on 07 July 2023

Less than half of directors are independent

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

Price target decreased by 8.0% to CN¥128

Price target decreased by 8.5% to CN¥127

Hangzhou Tigermed Consulting Co., Ltd. (SZSE:300347) acquired Marti Farm d.o.o. za trgovinu i usluge.

Executive VP & Executive Director recently sold CN¥7.5m worth of stock

Co-Founder recently sold CN¥477m worth of stock

Price target decreased to CN¥135

Less than half of directors are independent

Price target decreased to CN¥135

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Third quarter 2022 earnings: Revenues exceed analyst expectations

Hangzhou Tigermed Consulting Co., Ltd. Announces Chief Financial Officer Changes

Investor sentiment improved over the past week

Hangzhou Tigermed Consulting Co., Ltd. to Report Q3, 2022 Results on Oct 25, 2022

Hangzhou Tigermed Consulting Co., Ltd. Announces Change of Employee Supervisor of Committee

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Hangzhou Tigermed Consulting Co., Ltd. to Report First Half, 2022 Results on Aug 25, 2022

Price target increased to CN¥158

Investor sentiment improved over the past week

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

Investor sentiment improved over the past week

Hangzhou Tigermed Consulting Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 31 May 2022

Hangzhou Tigermed Consulting Co., Ltd Approves Final Dividend to for the Year Ended December 31, 2021

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent